Technical Analysis for AVXL - Anavex Life Sciences Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Crossed Above 20 DMA | Bullish | 3.78% | |
| Wide Bands | Range Expansion | 3.78% | |
| Fell Below 20 DMA | Bearish | 10.32% | |
| Wide Bands | Range Expansion | 10.32% | |
| Gapped Down | Weakness | 10.32% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 2.01% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.01% | |
| Crossed Above 20 DMA | Bullish | 2.01% | |
| NR7 | Range Contraction | 2.01% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | 2 days ago |
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2022
Anavex Life Sciences Corp. Description
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Pain Chemical Compounds Neuroscience Alzheimer's Disease Alzheimer's Central Nervous System Disease Lewy Body Dementia Piperidines Treatment Of Alzheimer's Disease Neuroprotection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 31.5 |
| 52 Week Low | 7.13 |
| Average Volume | 887,463 |
| 200-Day Moving Average | 15.25 |
| 50-Day Moving Average | 10.55 |
| 20-Day Moving Average | 8.77 |
| 10-Day Moving Average | 8.47 |
| Average True Range | 0.76 |
| RSI | 52.38 |
| ADX | 31.16 |
| +DI | 18.05 |
| -DI | 19.41 |
| Chandelier Exit (Long, 3 ATRs) | 8.36 |
| Chandelier Exit (Short, 3 ATRs) | 9.41 |
| Upper Bollinger Bands | 10.16 |
| Lower Bollinger Band | 7.37 |
| Percent B (%b) | 0.81 |
| BandWidth | 31.77 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.65 |
| MACD Histogram | 0.2366 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.70 | ||||
| Resistance 3 (R3) | 10.59 | 10.13 | 10.52 | ||
| Resistance 2 (R2) | 10.13 | 9.85 | 10.18 | 10.46 | |
| Resistance 1 (R1) | 9.87 | 9.68 | 10.00 | 9.98 | 10.40 |
| Pivot Point | 9.41 | 9.41 | 9.47 | 9.46 | 9.41 |
| Support 1 (S1) | 9.15 | 9.13 | 9.28 | 9.26 | 8.84 |
| Support 2 (S2) | 8.69 | 8.96 | 8.74 | 8.78 | |
| Support 3 (S3) | 8.43 | 8.69 | 8.72 | ||
| Support 4 (S4) | 8.54 |
